Nathalie Scholler, holder of M.D. and Ph.D. degrees, is a tenure-track Assistant Professor at the Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Scholler is an Immunologist by training and has been studying tumor immunity of ovarian cancer over more than 10 years. She also has a long-standing expertise in the field of antibody development. As a Staff Research Scientist at PNRI, Seattle, WA, USA, Scholler created an ELISA assay that is now commercialized by Fujirebio, Inc. as Mesomark. She then directed the Translational and Outcomes (TOR) Laboratory headed by Dr. Nicole Urban, ScD, in the Public Sciences division of the Fred Hutchinson Cancer Research Center, Seattle, WA,USA, and the bead-based assays developed by her laboratory have been central to several epidemiological studies for early detection of ovarian cancer. When she joined the University of Pennsylvania, she brought in the yeast-display recombinant antibody (scFv) technology and her laboratory has used this platform to develop and screen two novel antibody libraries derived from patients with autoimmune disease or ovarian cancer. This work resulted in the identification of several novel scFvs directed against tumor-associated antigens, tumor vascular markers, and immunosuppressive molecules that are currently used to interrogate the tumor microenvironment in mouse models of ovarian cancers, to target nanoparticles for MRI imaging, and to create Chimeric Immune Receptors (CIRs) for T-cell therapy.
Biography Updated on 16 August 2012